Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Amended claims 1-4, 10-12, 18, 21, 25, 27, 31, 42, and 53 and new claims 54-59 are pending.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claim(s) 1-4, 10-12, 18, 21, 25, 27, 31, 42, and 53 and new claims 54-59 are rejected under 35 U.S.C. 103 as being unpatentable over Zheng WO2020163823 and Fan, Front Physiol. 2020 Dec 1;11:593630, 1-12 and Teng, Biology 2020, 9, 157, 1-18.
Fanis new and added to augment previous presented rationale.
According to Applicant the office action is improper. See page 9 of Remarks 09/17/2026.
Specifically, Applicant argues that
PNG
media_image1.png
82
718
media_image1.png
Greyscale
More specifically, Applicant arguments focuses on
PNG
media_image2.png
84
714
media_image2.png
Greyscale
and
Examiner does not address the Killing of Senescent Cells, for example as in claim 42 and the unexpected results as a result relating in view of this.
Response:
Applicants arguments are not persuasive.
The inherent property (degrading BcL2 and BcL-xl) of the instantly pictured active ingredient (Zheng compound), admitted to by the applicant at top of specification page 2 is inexorably linked to the diseases in the amended claimed methods as explained below:
According to Fan, (page 6, column A) , under section
Inhibition of Bcl-2 Family Protein Sensitizes Senescent Cells It has been shown that
Bcl-xl, Bcl-w, and Bcl-2 inhibitors ABT-263 and ABT-737 could selectively clear senescent cells by more than 65%.
Also see Fan at page 6, Column B,
Bcl-xl inhibitors, A1331852 and A1155463, can efficiently increase caspase 3/7 activity and cellular apoptosis in senescent HUVEC and IMR90 cells.
According to Teng, Abstract
Venetoclax, a BCL2 inhibitor, approved by FDA for chronic lymphocytic leukemia, inhibited stellate cell proliferation, showed promising anti-fibrotic effects in miR-122 knockout mice. miR-122 in regulating liver fibrosis.
Also see Teng, page 2:
Venetoclax, an FDA approved BCL2 inhibitor for leukemia, suppressed proliferation of a human HSC cell line and expression of fibrotic genes. Venetoclax also reduced the collagen level and expression of fibrotic genes in the mice livers depleted of miR-122. These observations provide us a strong rationale to block liver fibrosis by targeting BCL2.
Taken together, one of skill in the art would expect that the compound of Zhao having similar properties of compound ABT-263 and ABT-737, A1331852, A1155463 and Venetoclax.
Since all these compounds share same biochemical property, one of skill in the art would have similar therapeutic use.
Simple substitution of one known element for another to obtain predictable results is obvious, even though it is acknowledged that Zhao compound is a Bcl2 degrader.
Protein degraders (like PROTACs) and traditional occupancy-based inhibitors targeting the same protein can exhibit highly similar pharmacological properties.
As such one of skill in the art would have reasonable expectation of success in choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success. Here the ‘solutions’ refers to substituting a degrader for inhibitor.
Examination guidelines as to the position taken is predicated on the following:
The new use for an old compound (of Zheng) must be novel as to the use directed and unobvious. The new use (if any) must account for the possibility that the underlying mechanism (inherent BcL-2 & Bcl-xl degradation and inhibition) for the new therapy (NASH, NAFLD, insulin resistance, diabetes) is the same mechanism that allows for a prior art treatment using the same compound (or its obvious version, see Venetoclax above).
Obviousness can be established by combining or modifying the teachings of the prior art to produce the claimed invention where there is some teaching, suggestion, or motivation to do so found either in the references themselves or in the knowledge generally available to one of ordinary skill in the art.
A reference is good not only for what it teaches by direct anticipation but also for what one of ordinary skill in the art might reasonably infer from the teachings. (In re Opprecht 12 USPQ 2d 1235, 1236 (Fed Cir. 1989); In re Bode 193 USPQ 12 (CCPA) 1976). In light of the foregoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a). From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.
The Supreme Court in KSR International Co. v. Teleflex Inc., 550 U.S. 398, 127 S. Ct. 1727, 82 USPQ2d 1385, 1395-97 (2007) identified a number of rationales to support a conclusion of obviousness which are consistent with the proper “functional approach” to the determination of obviousness as laid down in Graham. The key to supporting any rejection under 35 U.S.C. 103 is the clear articulation of the reason(s) why the claimed invention would have been obvious. The Supreme Court in KSR noted that the analysis supporting a rejection under 35 U.S.C. 103 should be made explicit.
Exemplary rationales that may support a conclusion of obviousness include:
(A) Combining prior art elements according to known methods to yield predictable results;
(B) Simple substitution of one known element for another to obtain predictable results;
(C) Use of known technique to improve similar devices (methods, or products) in the same way;
(D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results;
(E) “Obvious to try” – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success;
(F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art;
(G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention.
Note that the list of rationales provided is not intended to be an all-inclusive list. Other rationales to support a conclusion of obviousness may be relied upon by Office
Accordingly, the claims do not recite an unobvious distinction over the prior art. Further, a reference is relevant not only for what it expressly teaches, but also for what it would have conveyed to one of ordinary skill in the art. See In re Opprecht, 12 USPQ2d 1235, 1236 (Fed. Cir. 1989); In re Bode, 193 USPQ 12 (CCPA 1976). In light of the foregoing discussion, the Examiner finds that the claimed subject matter as a whole would have been obvious to one of ordinary skill in the art at the time the invention was made, in view of the cited references and the knowledge generally available in the art. Accordingly, the claims are rejected under 35 U.S.C. § 103.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claim(s) 1-4, 10-12, 18, 21, 25, 27, 31, 42, and 53-59 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the specification, while being enabling for the pictured compound/active ingredient, does not reasonably provide enablement for making any of its polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled compound. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The specification does not reasonably provide enablement for making hydrates of the claimed compounds.
The determination that "undue experimentation" would have been needed to make and use the claimed invention is not a single, simple factual determination. Rather, it is a conclusion reached by weighing all the relevant factual considerations.
Enablement is considered in view of the Wands factors (MPEP 2164.01 (a)). These include: (1) breadth of the claims; (2) nature of the invention; (3) state of the prior art; (4) amount of direction provided by the inventor; (5) the level of predictability in the art; (6) the existence of working examples; (7) quantity of experimentation needed to make or use the invention based on the content of the disclosure; and (8) relative skill in the art.
All of the factors have been considered with regard to the claims, with the most relevant factors discussed below:
The pictured active ingredient in the claimed is known in the prior art of Zheng WO2020163823. Zheng disclosure does have the terms polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled compound. While Zheng teach composition (and kits), neither the specification nor Zheng teach how to make polymorph, co-crystal, tautomer, stereoisomer, or isotopically labeled compound.
There is no disclosure on how to make any of these in predictable manner. There is no chemistry methods or experimental procedure on how to make, for example, isotopically labelled compounds. The molecular formula of the pictured compounds is C82H105ClF3N11O11S4. It is elementary knowledge that different atoms C, H, Cl, F, N, O, S each have different number of isotopes. Consider for example, it is known that Sulfur (16S) has 23 known isotopes with mass numbers ranging from 27 to 49, four of which are stable: 32S (94.85%), 33S (0.76%), 34S (4.37%), and 36S (0.016%). Likewise Oxygen has 3 stable isotopes and a total of 18 known isotopes ranging from mass numbers 11 to 28. And so on, making the number of possible isotopically labelled analogs of C82H105ClF3N11O11S4 is large that finds no support in the specification. Similarly, with 6 stereo centers in the pictured compound, 64 isomers are possible. Only the pictured compound is commercially available; there is no disclosure as to where to procure any other possible recited versions of the commercial compound. These cannot be willed into existence. In addition, for example, that all these stereoisomers would have similar predictable properties defies commonsense medicinal chemistry. See for example, according to Sundaresan, Protein Science (2002), 11:1330–1339 ‘stereoselectivity in biological molecular recognition processes is extremely important for rational drug design’.
MPEP 2164.01(a) states, “A conclusion of Iack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. ln re Wright, 999 F.2d 1557,1562, 27 USPQ 2d 1510, 1513 (Fed. Cir. 1993).'' That conclusion is clearly justified here. Thus, undue experimentation would be required.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to NIZAL S CHANDRAKUMAR whose telephone number is (571)272-6202. The examiner can normally be reached M-F 8-5 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/NIZAL S CHANDRAKUMAR/ Primary Examiner, Art Unit 1625